Allan Camaisa sold $16k of CLDI
CEO and Chairman of the Board at Calidi Biotherapeutics, Inc.. 10,000 shares at an average of $1.62, traded Dec 17, 2024, filed Dec 18, 2024.
Score components
- +25RoleCEO
- 0Trade size$16k at market
- +5Share of holdings soldSold 13% of holdings
- 0ClusterNo other insider selling within 14 days
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m -37.9%, 3m -44.1%, 6m -79.5%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001493152-24-050675, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Dec 17, 2024 | SOpen-market sale Common Stock | -10,000 | $1.62 | $16k | 66,712 | Dec 18, 2024 |
Related signals
Other insiders at Calidi Biotherapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 15Weak | CLDIsell Calidi Biotherapeutics, Inc. | Allan Camaisa CEO and Chairman of the Board | $1,237 850 shares | -1% | |
| 63Notable | Calidi Biotherapeutics, Inc. | Andrew C. Jackson Chief Financial Officer | $5,000 2,500 shares | - | |
| 71Notable | Calidi Biotherapeutics, Inc. | Scott Leftwich director | $250k 125,000 shares | +2212% | |
| 73Notable | Calidi Biotherapeutics, Inc. | Eric E Poma Chief Executive Officer | $50k 25,000 shares | - | |
| 69Notable | Calidi Biotherapeutics, Inc. | James A Schoeneck director | $150k 75,000 shares | +6614% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.